Trial Outcomes & Findings for Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc (NCT NCT01218542)

Patients were recruited at Winship Cancer Institute of Emory University from September 2010 to September 2015.

Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc

The cumulative incidences of recurrence locally and in the whole brain were reported at the patient level.

Defined as period of time from study entry to to death from any cause or brain tumor recurrence or progression.

Defined time from study entry to death from any cause.

Neurological test score were assessed using the Hopkins Verbal Learning Test-Revised (HVLT). In the HVLT 12 words are read and the participant is asked to recall them, this is completed 3 times. Total words recalled are summed to give a score for Total Recall (0-36, higher scores demonstrated better recall). Delayed recall is conducted 20-25 minutes later on the same list of 12 words (scored 0-12 with higher scores demonstrating better recall). Retention is calculated as the percent of words recalled (scored 0-100, higher scores representing better recall). Recognition Discrimination is tested by a series of yes/no responses from the participant identifying 12 target words from a list of 24 and calculated by the number of true positives minus the number of true negatives with higher scores indicating a better outcome.

The Functional Assessment of Cancer Therapy-Brain (FACT-Br) were summed to create the FACT brain trial outcome index (FACT-BR TOI), FACT general (FACT-G), and FACT brain total (FACT-BR Total). Three FACT scales were calculated. The higher the value the better the score, i.e., the better the quality of life perceived by patient. FACT BR TOTAL (FACT-G + BrCS, possible range 0 - 200) FACT-BR TOI (Trial Outcome Index = Physical Well Being \_ Functional Well Being +BrCS, possible range 0 - 148) FACT-G (Fact General, possible range 0 - 108)